Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 80

1.

Management of hepatic encephalopathy in Germany: a survey among physicians.

Labenz C, Adarkwah CC, Wörns MA, Miehlke S, Hofmann WP, Buggisch P, Galle PR, Frieling T, Labenz J.

Z Gastroenterol. 2020 Jan;58(1):49-56. doi: 10.1055/a-1010-6974. Epub 2020 Jan 13.

PMID:
31931540
2.

Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections.

Dietz J, Spengler U, Müllhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer KH, Berger A, Matschenz K, Buggisch P, Backhus J, Zizer E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C; European HCV Resistance Study Group.

Clin Gastroenterol Hepatol. 2019 Nov 6. pii: S1542-3565(19)31260-1. doi: 10.1016/j.cgh.2019.10.051. [Epub ahead of print]

PMID:
31706062
3.

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.

Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pröls M, Manns MP, Fickert P, Trauner M; Austrian/German NAFLD-norUDCA study group.

Lancet Gastroenterol Hepatol. 2019 Oct;4(10):781-793. doi: 10.1016/S2468-1253(19)30184-0. Epub 2019 Jul 22.

PMID:
31345778
4.

Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.

Lucendo AJ, Miehlke S, Schlag C, Vieth M, von Arnim U, Molina-Infante J, Hartmann D, Bredenoord AJ, Ciriza de Los Rios C, Schubert S, Brückner S, Madisch A, Hayat J, Tack J, Attwood S, Mueller R, Greinwald R, Schoepfer A, Straumann A; International EOS-1 Study Group.

Gastroenterology. 2019 Jul;157(1):74-86.e15. doi: 10.1053/j.gastro.2019.03.025. Epub 2019 Mar 26.

5.

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment.

Knop V, Hofmann WP, Buggisch P, Klinker H, Mauss S, Günther R, Hinrichsen H, Hüppe D, Pfeiffer-Vornkahl H, Simon KG, Berg T, Manns MP, Friedrich-Rust M; German Hepatitis C-Registry.

J Viral Hepat. 2019 Feb;26(2):224-230. doi: 10.1111/jvh.13021. Epub 2018 Nov 8.

PMID:
30315694
6.

Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry.

Dultz G, Müller T, Petersen J, Mauss S, Zimmermann T, Muche M, Simon KG, Berg T, Zeuzem S, Hüppe D, Böker K, Wedemeyer H, Welzel TM; Leberstiftungs-GmbH Deutschland.

Drugs Aging. 2018 Sep;35(9):843-857. doi: 10.1007/s40266-018-0572-0.

PMID:
30084012
7.

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.

Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group.

Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13.

PMID:
29146520
8.

Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis.

van der Meer AJ, Maan R, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL.

J Gastroenterol Hepatol. 2016 Jun;31(6):1168-76. doi: 10.1111/jgh.13252.

9.

Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study.

Hofmann WP, Mauss S, Lutz T, Schober A, Böker K, Moog G, Baumgarten A, Pfeiffer-Vornkahl H, Alshuth U, Hüppe D, Wedemeyer H, Manns MP, Schott E.

PLoS One. 2015 Jul 31;10(7):e0134839. doi: 10.1371/journal.pone.0134839. eCollection 2015.

10.

Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort.

Mauss S, Böker K, Buggisch P, Christensen S, Hofmann WP, Schott E, Pfeiffer-Vornkahl H, Alshuth U, Hüppe D.

Z Gastroenterol. 2015 Jul;53(7):644-54. doi: 10.1055/s-0034-1399383. Epub 2015 Jul 13.

PMID:
26167694
11.

Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters.

van der Meer AJ, Hansen BE, Fattovich G, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Ieluzzi D, Zeuzem S, Hofmann WP, de Knegt RJ, Veldt BJ, Janssen HL.

Gut. 2015 Feb;64(2):322-31. doi: 10.1136/gutjnl-2013-305357. Epub 2014 May 9.

PMID:
24815676
12.

Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta.

Kabaçam G, Wedemeyer H, Savaş B, Keskin O, Dalekos G, Tabak F, Idilman R, Erhardt A, Yalçın K, Bozdayi MA, Bozkaya H, Manns M, Dienes H, Yurdaydın C; HIDIT-1 Study Group.

Liver Int. 2014 Sep;34(8):1207-15. doi: 10.1111/liv.12376. Epub 2013 Dec 5.

PMID:
24308704
13.

The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection.

van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL.

J Viral Hepat. 2014 Aug;21(8):568-77. doi: 10.1111/jvh.12185. Epub 2013 Oct 10.

PMID:
24118177
14.

Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis.

Dultz G, Seelhof M, Herrmann E, Welker MW, Friedrich-Rust M, Teuber G, Kronenberger B, von Wagner M, Vermehren J, Sarrazin C, Zeuzem S, Hofmann WP.

PLoS One. 2013 Aug 1;8(8):e71262. doi: 10.1371/journal.pone.0071262. Print 2013.

15.

Investigation of viral escape mutations within HCV p7 during treatment with amantadine in patients with chronic hepatitis C.

Vermehren A, Welsch C, Elsler U, Vermehren J, Herrmann E, Sarrazin C, von Wagner M, Susser S, Hofmann WP, Kronenberger B, Zeuzem S, Mihm U.

Antivir Ther. 2013;18(6):803-11. doi: 10.3851/IMP2663. Epub 2013 Jul 3.

PMID:
23824381
16.

Long-term follow-up of endoscopic therapy for stenosis of the biliobiliary anastomosis associated with orthotopic liver transplantation.

Albert JG, Filmann N, Elsner J, Moench C, Trojan J, Bojunga J, Sarrazin C, Friedrich-Rust M, Herrmann E, Bechstein WO, Zeuzem S, Hofmann WP.

Liver Transpl. 2013 Jun;19(6):586-93. doi: 10.1002/lt.23643.

17.

Long-term follow-up of endoscopic therapy in stenosis of the bilio-biliary anastomosis associated with orthotopic liver transplantation.

Albert JG, Filmann N, Elsner J, Moench C, Trojan J, Bojunga J, Sarrazin C, Friedrich-Rust M, Herrmann E, Bechstein WO, Zeuzem S, Hofmann WP.

Liver Transpl. 2013 Mar 22. doi: 10.1002/lt.22643. [Epub ahead of print]

PMID:
23526624
18.

Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs.

Peveling-Oberhag J, Herrmann E, Kronenberger B, Farnik H, Susser S, Sarrazin C, Zeuzem S, Hofmann WP.

J Viral Hepat. 2013 Apr;20(4):234-9. doi: 10.1111/jvh.12013. Epub 2012 Nov 15.

PMID:
23490367
19.

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL.

JAMA. 2012 Dec 26;308(24):2584-93. doi: 10.1001/jama.2012.144878.

PMID:
23268517
20.

Current standards in the treatment of chronic hepatitis C.

Hofmann WP, Sarrazin C, Zeuzem S.

Dtsch Arztebl Int. 2012 May;109(19):352-8. doi: 10.3238/arztebl.2012.0352. Epub 2012 May 11.

Supplemental Content

Loading ...
Support Center